- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05266378
Pectoralis Nerve Block and Quality of Recovery in Mastectomy Patients
The Effect of Pectoralis Nerve Block on Quality of Recovery in Patients Undergoing Breast-conservative Surgery
Effects of pectoralis nerve block on quality of recovery after breast surgery has been debated. We hypothesized there might exist relevant psychosocial factor or variable of pain sensitivity which would influence on the benefit of nerve block.
This study aims to assess effect of pectoralis nerve block on QoR-15 score in subgroups stratified by such factors.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study population All of patients will undergo partial mastectomy. 140 patients will be enrolled.
Intervention Pectoralis nerve block will be performed in the Block group.
Psychosocial factor screening Pain-detect, HADS, EQ-5D, PHQ-15 (somatic symptom), PCS (pain catastrophizing), BFI (big five inventory), HAM-A&D, Pressure algometry (Pain sensitivity), Quantitative sensory test (pinprick)
Study endpoints Quality of recovery (QoR)-15 Pain visual analogue scale Opioid consumption Breast Cancer Pain Questionnaire (BCPQ)
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Young Song
- Phone Number: 82-2-2019-6692
- Email: NEARMYHEART@yuhs.ac
Study Locations
-
-
-
Seoul, Korea, Republic of
- Recruiting
- Young Song
-
Contact:
- Young Song
- Phone Number: 82-2-2019-6629
- Email: gsirb@yuhs.ac
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients aged 20 to 80 years who underwent partial mastectomy for breast cancer.
Exclusion Criteria:
- Patients with a history of previous breast surgery
- Patients with a history of adverse reactions to local anesthetics
- Patients with a history of drug addiction
- Patients with cancer other than breast
- Patients with chronic pain who require analgesics
- History of hospitalization for psychiatric disorders
- Preoperative pulse oximetry (SpO2) < 95 %
- Left ventricular ejection fraction < 40%
- Moderate or severe hepatic impairment
- Body mass index over 35 kg/m2
- Blood clotting disorders
- Pregnant/lactating women
- Inability to understand consent forms and answer research questionnaires due to cognitive impairment
- Unable to read consent form (eg illiterate, foreigner, etc.)
- do not perform axillary lymph node dissection
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Block group
The group undergoing PECs block
|
The PECs block is performed immediately after induction of anesthesia, and 0.375% concentration of ropivacaine (carbiropivacaine injection, Fresinius Kavi Korea Co., Ltd.) is used with a 25 G 5 cm (or 8 cm) needle to induce ultrasound-guided pectoralis major (pectoralis major).
10mL (PECs I block) into the fascia between the pectoralis minor muscle) and the pectoralis minor muscle, and 20mL (PECs II block) between the pectoralis minor and serratus anterior muscle.
|
|
Placebo Comparator: Control group
The group not receiving PECs block
|
In this group, the PECs block was not implemented.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
QoR-15
Time Frame: Postoperative day 1
|
To compare the difference in the quality of recovery between groups, the QoR-15 questionnaire is administered on the 1st day after surgery.
|
Postoperative day 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Intensity of pain
Time Frame: Postoperative day 0, 1
|
Intensity of pain will be recorded by using VAS (0-10).
|
Postoperative day 0, 1
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Preoperative psychological factors: HADS
Time Frame: 1-5 days before surgery, 1st OPD visit after surgery
|
Presence of anxiety and depression symptoms will be assessed by HADS (Hospital Anxiety and Depression Scale) questionnaire.
|
1-5 days before surgery, 1st OPD visit after surgery
|
|
Preoperative psychological factors: EQ-5D
Time Frame: 1-5 days before surgery, 1st OPD visit after surgery
|
Presence of anxiety and depression symptoms will be assessed by EQ-5D.
|
1-5 days before surgery, 1st OPD visit after surgery
|
|
Preoperative psychological factors and pain sensitivity test: PHQ-15
Time Frame: 1-5 days before surgery, 1st OPD visit after surgery
|
Presence of anxiety, depression symptoms and pain sensitivity will be assessed by PHQ-15.
|
1-5 days before surgery, 1st OPD visit after surgery
|
|
Preoperative psychological factors and pain sensitivity test: pain catastrophizing scale
Time Frame: 1-5 days before surgery, 1st OPD visit after surgery
|
Presence of anxiety, depression symptoms and pain sensitivity will be assessed by pain catastrophizing scale.
|
1-5 days before surgery, 1st OPD visit after surgery
|
|
Preoperative psychological factors: big five inventory
Time Frame: 1-5 days before surgery, 1st OPD visit after surgery
|
Presence of anxiety and depression symptoms will be assessed by big five inventory.
|
1-5 days before surgery, 1st OPD visit after surgery
|
|
Preoperative psychological factors: HAM-A&D
Time Frame: 1-5 days before surgery, 1st OPD visit after surgery
|
Presence of anxiety and depression symptoms will be assessed by HAM-A&D.
|
1-5 days before surgery, 1st OPD visit after surgery
|
|
Patient State Index
Time Frame: perioperative period
|
Depth of anesthesia will be recorded by using frontal electroencephalogram (Patient State Index, The PSi is a processed EEG parameter that is related to the effect of anesthetic agents, and takes into consideration, among other factors: (1) changes in power in various EEG frequency bands; (2) changes in symmetry and synchronization between critical brain regions; and (3) the inhibition of regions of the frontal cortex.)
during operation
|
perioperative period
|
|
analgesic nociception index
Time Frame: perioperative period
|
Intensity of pain will be recorded by using analgesic nociception index during operation
|
perioperative period
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 3-2021-0468
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
Oncoliq US IncRecruitingBreast Cancer Female | Breast Cancer Detection | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Breast Cancer With Low to Intermediate HER2 Expression | Breast Cancer - Female | Breast Cancer (Early Breast Cancer) | Breast Cancer - Ductal Carcinoma in Situ (DCIS) | Breast Cancer - Infiltrating...Argentina
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast CancerUnited States
-
Joseph Baar, MD, PhDCompletedBreast Cancer | Stage I Breast Cancer | Inflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast CancerUnited States
-
Case Comprehensive Cancer CenterNational Institute on Minority Health and Health Disparities (NIMHD)CompletedCancer Survivor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of Maryland, BaltimoreSyndax PharmaceuticalsTerminatedStage I Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Triple-negative Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
National Cancer Institute (NCI)CompletedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast CancerUnited States
Clinical Trials on PECs block
-
Assiut UniversityNot yet recruiting
-
Assiut UniversityActive, not recruiting
-
Mansoura UniversityUnknownPost Mastectomy Pain Syndrome | After Breast Surgery
-
Antalya Training and Research HospitalCompletedAnalgesia | Anesthesia | Nerve Block | Cardiac Implantable Electronic DeviceTurkey
-
University of British ColumbiaRecruitingBreast Reconstruction | Mastectomy | Nerve Block | Surgery, PlasticCanada
-
Ain Shams UniversityCompleted
-
Aretaieion University HospitalCompletedPain, Postoperative | Breast Cancer | Breast Neoplasms | Chronic Pain | Anesthesia | Breast Cancer Female | Pain Syndrome | Breast Pain | Breast Soft Tissue NeoplasmGreece, Cyprus
-
Suez Canal UniversityCompletedBreast Cancer | MastectomyEgypt
-
Baskent UniversityCompletedBreast NeoplasmsTurkey
-
Azienda Ospedaliera SS. Antonio e Biagio e Cesare...Enrolling by invitationBreast Cancer | Breast Neoplasms | Breast CarcinomaItaly